Quick search:
Content Search
Result Content Research
Result Content Research
1 Humira for plaque psoriasis: Dosage, how it works, and more
2 Optum Rx Executive: Biosimilars Have Momentum But It Will Take the Approval of Humira, Other Commonly Prescribed Biologics for Them to Really Take Off
3 Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
4 Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®
5 AbbVie looks set to recreate Humira patent thicketing success following Imbruvica victory | IAM
6 New Humira decision changes venue selection playbook for US biosimilar patent disputes | IAM
7 AbbVie's Imbruvica patent win sets up solid growth path after Humira's decline: analyst
8 AbbVie Humira Lawsuit Withstands Alvotech Attack :: Generics Bulletin
9 Is AbbVie a Bad News Buy?
10 AbbVie, Eisai, And EA Pharma Launch "Humira Support Tool Ordering Service For Patients"
11 Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Report 2021-2026: Adalimumab (Humira) is Currently Dominating the $10 Billion Market
12 AbbVie's Humira Patent Claims Survive Dismissal Bid
13 Humira: Side Effects, Uses, Cost, How to Inject, and More
14 Is AbbVie's 4.9% Dividend Yield Safe?
15 Humira: Side effects and what to do about them
16 Humira and dosage: Strengths, forms, when to use, and more
17 Humira Dosage: Forms, Strengths, How to Use, and More
18 Cimzia vs. Humira: What's the difference between them?
19 AbbVie's biosimilar erosion woes overstated
20 Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close
21 JAK inhibitors from Pfizer, AbbVie and Lilly hit with dreaded FDA heart safety, cancer warnings
22 British Columbia Switches From Humira to 5 Biosimilar Versions
23 Stelara vs. Humira: Is One of Them Right for You?
24 Humira Market Present Scenario 2021-28 | AbbVie, Eisai, Cadila Healthcare
25 Humira for Crohn's Disease: Safety, Efficacy, and Side Effects
26 Jim Crawford: Congress against Americans
27 Humira Drug / Medicine Information
28 Skyrizi vs. Humira: Is One of Them Right for You?
29 When Humira Finally Faces Biosimilar Competition, Losses For AbbVie May Not Be As Steep As Expected, Say Analysts
30 AbbVie Selloff Overdone, Stock Remains Undervalued: BMO
31 AbbVie repeatedly hiked Humira, Imbruvica prices and abused patents to keep competitors at bay: report
32 HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
33 Alberta, Canada, Begins Mandating Switches From Originator to Biosimilar Humira
34 2 Embarrassingly Cheap Dividend Stocks to Buy
35 Alvotech challenges AbbVie on US Humira exclusivity
36 Top in rheumatology: Humira biosimilars, refractory Lyme arthritis
37 Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst
38 Johnson & Johnson spotlights safety edge after Stelara's near miss against Humira in Crohn's
39 Otezla vs. Humira: How These Drugs Compare
40 Drug delivery capsule could replace injections for protein drugs: The new pill can inject large quantities of monoclonal antibodies and other drugs into the lining of the stomach after being swallowed.
41 AbbVie's Humira Sales Drop Internationally from Biosimilar Competition, but Not in the US
42 Humira: Side effects, cost, uses, and more
43 European Agency Recommends Two New Adalimumab Biosimilars
44 Hidradenitis suppurativa ripe for competition with Humira the only approved biologic
45 HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
46 Cancer drugs show big sales rise in 2020; AbbVie's Humira again tops list
47 Top Qualcomm exec slams Apple; NTT and Oppo agree SEP deal; Uber and Cruise form auto IP group; Square talks crypto patents; More Toshiba IP sales; plus much more | IAM
48 AbbVie's blockade of cheaper Humira options
49 Alvotech Files Suit to Invalidate Humira Patents
50 Does Medicare cover Humira? Coverage, eligibility, and costs
51 AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
52 AbbVie: The FDA Decision On RINVOQ Likely Means Trouble
53 AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says
54 AbbVie Hopefuls Skyrizi and Rinvoq Show Promise in Quest to Succeed Humira
55 Humira's reign as TV ad king is over as AbbVie shifts spending to Rinvoq and Skyrizi
56 Why Wall Street Thinks This Dirt Cheap Value Stock Could Soar
57 AbbVie's successful hard-ball with Humira legal strategy unlikely to spawn
58 Humira Bags Another FDA Approval, This Time for Pediatric Ulcerative Colitis
59 AbbVie exec details upbeat plan for Rinvoq, Skyrizi as Humira copycats near: analyst
60 These Promising Clinical Results Could Be Huge for Amgen Investors
61 Adalimumab Biosimilars Face Product Obsolescence Before Launch
62 Adalimumab: Sold Under the Brand Name Humira
63 FDA head Janet Woodcock raises patent-related concerns to PTO director
64 HUMIRA (Adalimumab) Biosimilars Market Research Report 2021
65 AbbVie's Humira Still Number 1 in Drug Sales
66 VIDEO: Stelara, Humira safely, effectively treat CD
67 AbbVie's post-Humira life looks brighter with Skyrizi psoriatic arthritis win
68 Biosimilar Cyltezo® shows similar clinical outcomes to Humira® in treatment of moderate-to-severe chronic plaque psoriaris
69 AbbVie's plan to push Rinvoq to counter Humira biosimilar surge dampens
70 The pros and cons of immune modulating drugs
71 7th Circuit Hears Oral Arguments in Humira “Patent Thicket” Antitrust Case
72 EU Approves Yuflyma, Humira Biosimilar, for Chronic Inflammatory Diseases
73 Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive
74 AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi
75 AbbVie CEO summoned to Congress—again—to answer questions on Humira pricing, patenting
76 AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
77 AbbVie chases its next golden goose in a post-Humira future with new ulcerative colitis data for Rinvoq
78 DOD taps Pharm-Olam for repurposed Humira COVID-19 test
79 AbbVie Enjoys Strong Second Quarter as Rinvoq Gears Up to Succeed Humira
80 Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment
81 J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi
82 Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
83 Abbvie bets on strong Humira rebound
84 This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
85 Rinvoq psoriasis delay adds to Abbvie's Humira concerns
86 Humira becomes first treatment approved for pyoderma gangrenosum
87 AbbVie drops Humira TV spend; Sanofi and Regeneron, Novo Nordisk step up on March pharma list
88 Celltrion unveils Humira biosimilar's P3 trial results in Europe
89 AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs
90 AbbVie says biosim maker Alvotech recruited a manufacturing exec to steal trade secrets on Humira
91 Korean biosimilars of Humira ready to enter Japan, Europe
92 Growing Competition for the World’s Most Profitable Drug as Multiple New Adalimumab Biosimilars Launch
93 Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfolio
94 Interchangeable Biosimilars: Insulin Likely First But Humira May Be More Important Precedent
95 IBD and Pediatric Arthritis: Exploring the Link
96 FDA approves Hulio, sixth Humira biosimilar
97 Humira Improved
98 Boehringer says data supports interchangeability of Cyltezo with Humira
99 AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi
100 AbbVie confident of fighting off Alvotech challenge on Humira